Areteia Therapeutics Granted ILAP Designation from UK MHRA for Oral Dexpramipexole for Eosinophilic Asthma
Areteia Therapeutics today announced that the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has granted an Innovation Passport under the Innovative Licensing and Access Pathway (ILAP) to dexpramipexole, an eosinophil lowering small molecule, that has recently entered Phase III clinical development.
The Innovation Passport is the first step in the ILAP process, triggering the MHRA and its partner agencies, including the National Institute for Health and Care Excellence (NICE), the Scottish Medicines Consortium (SMC) and National Health Service (NHS) England, to chart a roadmap for regulatory and development milestones with the goal of early patient access in the U.K.
“It is great to see that in granting an Innovation Passport, the MHRA is as excited as we are about the potential for dexpramipexole,” said Jorge Bartolome, Chief Executive Officer of Areteia Therapeutics. He added, “If approved, dexpramipexole would represent the first oral drug for eosinophilic asthma patients, offering an alternative to injectable biologics.”
Dexpramipexole inhibits the maturation and release of eosinophils in bone marrow, based on evidence from cell cultures and human biopsies, thereby lowering peripheral blood eosinophil levels. Most recently in a Phase II study (EXHALE-1) in patients with moderate-to-severe eosinophilic asthma, treatment with dexpramipexole resulted in a significant, dose-dependent reduction in blood absolute eosinophil count at all doses tested (dexpramipexole doses of 37.5 mg, 75 mg, or 150 mg twice daily) compared to placebo. Dexpramipexole was well tolerated in the trial, with adverse events balanced across treatment and placebo groups, no serious adverse events, and no adverse events leading to discontinuation.
About Areteia Therapeutics
Areteia Therapeutics (areteiatx.com) is a clinical stage biotechnology company committed to putting asthma patients in better control of their disease and lives by developing the first potential oral drug for eosinophilic asthma. Areteia’s lead drug candidate is dexpramipexole, a first-in-class oral eosinophil maturation inhibitor. Areteia was created by Population Health Partners and Knopp Biosciences. A syndicate of leading life sciences and strategic investors led by Bain Capital Life Sciences with participation from Access Biotechnology, GV, ARCH Venture Partners, Saturn Partners, Sanofi, Maverick Capital, and Population Health Partners, has committed to invest up to $350 million in Series A financing to establish Areteia and advance dexpramipexole through Phase 3 clinical trials, secure commercial supply, and pursue potential next-generation medicines. Areteia is conducting late-stage development including three Phase 3 clinical trials of dexpramipexole in partnership with Population Health Partners’ development unit, Validae Health.
About Eosinophilic Asthma
Asthma disrupts the lives of more than a quarter of a billion people worldwide. More than half of asthma patients have eosinophilic asthma, which is driven by an oversupply of eosinophils, a type of white blood cell, in blood and tissue. By inhibiting the maturation of eosinophils, oral dexpramipexole acts in a way similar to injectable anti-IL-5 biologic therapies. The asthma biologic market is experiencing growth of 10% per year and is valued at around $8 billion, with IL-5 biologic therapies representing greater than $3 billion of that figure. If approved as a first-to-market oral drug, dexpramipexole could provide a compelling alternative to injectable biologics, and could potentially be used earlier in the asthma treatment paradigm to prevent progression of disease.
The U.K. Medicines and Healthcare products Regulatory Agency (MHRA) launched ILAP at the start of 2021 in order to accelerate the development and access to promising medicines in the early stages of development. The pathway, part of the UK’s plan to attract life sciences development in the post-Brexit era, features enhanced input and interactions with MHRA and other stakeholders. Other benefits of ILAP include access to a range of development tools, such as the potential for a 150-day accelerated Marketing Authorization Application (MAA) assessment, rolling review and a continuous benefit risk assessment.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230223005103/en/
Tamsin Berry Tamsin.Berry@areteiatx.com
Mark Kreston Mark.Kreston@areteiatx.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Truespeed accelerates fiber network expansion with Adtran23.3.2023 16:00:00 EET | Press release
Adtran today announced that Truespeed is leveraging its fiber broadband technology to provide high-speed connectivity to more customers across the South West of England. The new network includes Adtran’s XGS-PON technology, which enables the service provider to deliver current speed tiers of up to 900Mbit/s to households and up to 10Gbit/s to its enterprise customers. The multigigabit solution empowers Truespeed to connect subscribers significantly faster while streamlining its infrastructure with fewer equipment locations in the network. “Too often, broadband providers fail to deliver services that match their marketing hype. At Truespeed, we do things differently. We’re harnessing the most advanced software-defined access innovations available to provide fiber connectivity all the way into our customers’ homes and business premises. With Adtran’s open and programmable technology, we can guarantee ultra-fast speeds and 24/7 reliability,” said James Lowther, CEO of Truespeed. “We’ve al
American Express Reveals 2023 Top Travel Trends23.3.2023 16:00:00 EET | Press release
American Express Travel® released their 2023 Global Travel Trends Report today, highlighting four global trends inspiring people to travel this year: This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230323005091/en/ American Express Travel's 2023 Global Travel Trends Report The Rise of “Set-Jetting”: Popular movies, TV shows and social media are inspiring people to travel to places they see onscreen, like Italy, Paris, Yellowstone, and London Delicious Destinations: From top restaurants to local favorites to cooking classes, people are choosing their next destination based on what they’ll eat A Wellness Wave: Restorative vacations are on the rise as travelers prioritize self-care and mental and physical health Traveling Off the Beaten Path: Travelers want to discover hidden gems and support the local community when they visit The report, based on survey data from travelers from the United States, Australia, Canada, Mexico, Jap
FitXR expands VR Fitness offering to PICO23.3.2023 16:00:00 EET | Press release
FitXR is continuing to expand its popular virtual reality (VR) fitness offering with the UK, EU and Asia markets by launching on the popular PICO VR headsets. FitXR’s launch on PICO represents its commitment to make VR fitness accessible to all, irrespective of the user’s preference in hardware choice. As the mass market appeal in VR continues to grow, it will bring with it increased interest in hardware developers, innovation and consumer choice and in turn the desirability in multi-platform offerings like FitXR. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230323005314/en/ (Photo: Business Wire) In January 2023, FitXR launched two new studio offerings: Sculpt and Combat, to add to its already robust suite of offerings that include High Intensity Interval Training (HIIT), Dance and Box workout options. The launch of Sculpt (workouts inspired by barre, pilates, and isometric strength training) and Combat (workouts inspired
Altum Technologies Selected by Chevron Technology Ventures for Catalyst Program23.3.2023 16:00:00 EET | Press release
Altum Technologies, a Finnish company that has developed a patented method of cleaning technology, has been selected to participate in Chevron Technology Ventures (CTV) Catalyst Program. The deep tech company has developed a market-leading power ultrasound solution that improves process efficiency without stopping production. The collaborative program gives Altum Technologies the platform to further advance and deploy its Zero Process Downtime (ZPD) technology globally. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230323005027/en/ Altum Technologies has been selected to participate in Chevron Technology Ventures (CTV) Catalyst Program. The deep tech company has developed a market-leading power ultrasound solution that improves process efficiency without stopping production. (Graphic: Business Wire) Fouling and scaling are problems in most industrial processes that causeperiodic planned and unplanned shutdowns for difficult
AI/ML Capabilities Fall Short of Executive Expectations, According to a New Global Study by SoftServe23.3.2023 14:05:00 EET | Press release
New data released today by SoftServe indicates a dramatically different understanding of the value of artificial intelligence and machine learning (AI/ML) among executives at software and digital native companies. Interest in AI/ML has been heightened with the recent release of tools such as ChatGPT and the rollout of AI-powered Microsoft Bing. However, SoftServe's survey of nearly 600 IT leaders across nine countries tells a story of significant eagerness for AI/ML, but a great disappointment with it. While 56% say leadership should consider AI/ML an urgent priority to drive business results, 52% say it should be a priority to retain and appeal to skilled talent. Conversely, 72% of IT leaders say their executive team does not fully understand the technical capabilities of AI/ML and its potential for business success. Furthermore, of those surveyed, 42% say their leadership is not treating AI/ML as urgently as it should be — to the point where this vital investment is falling down the
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.Visit our pressroom